Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC.
AVATAX
Retrospective Multicenter Study of Paclitaxel in Combination With Bevacizumab in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC).
1 other identifier
observational
320
1 country
15
Brief Summary
The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2019
Shorter than P25 for all trials
15 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 5, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 5, 2020
CompletedFirst Submitted
Initial submission to the registry
November 9, 2020
CompletedFirst Posted
Study publicly available on registry
November 23, 2020
CompletedNovember 23, 2020
November 1, 2020
8 months
November 9, 2020
November 20, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Progression-free survival
Progression-free survival with paclitaxel-bevacizumab, i.e., the time from the start of paclitaxel-bevacizumab treatment to cancer progression, estimated at 12 months in the general population.
Up to 12 months
Secondary Outcomes (8)
Drugs administration dosage description
Up to 12 months
Objective response rate and control rate
Up to 12 months
Overall survival Rate
Up to 12 months
Objective Response Rate
Up to 12 months
Progression-Free Survival Rate
Up to 12 months
- +3 more secondary outcomes
Eligibility Criteria
The study will include all eligible patients who started paclitaxel-bevacizumab between January 1, 2010 and May 1, 2018. The number of patients is estimated to be approximately 200.
You may qualify if:
- At least 18 years old;
- Histologically or cytologically confirmed diagnosis of non-epidermal NSCLC;
- Advanced stage IV disease at the start of treatment with paclitaxel-bevacizumab according to TNM 7/8th edition classification;
- Treatment with paclitaxel-bevacizumab received as second-line therapy or beyond, in a clinical trial or not;
- Alive patients not opposed to the use of their data
You may not qualify if:
- Patient under guardianship or curatorship at the date of the study ;
- Patients alive at the time of the study who are opposed to the use of their data
- Opposition to the use of their data expressed during the lifetime of patients who died at the time of the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Centre Hospitalier Annecy Genevoislead
- University Hospital, Grenoblecollaborator
Study Sites (15)
Hôpital Ambroise Paré AP-HP
Boulogne-Billancourt, France
Centre Hospitalier Universitaire Brest
Brest, France
Centre Hospitalier Métropole Savoie
Chambéry, France
Centre Hospitalier Intercommunal de Créteil
Créteil, France
Centre Hospitalier Universitaire Grenoble Alpes
Grenoble, France
Centre Hospitalier de Versailles André Mignot
Le Chesnay, France
Centre Hospitalier Universitaire de Lille
Lille, France
Centre Léon Bérard Lyon
Lyon, France
Hospices Civils de Lyon
Lyon, France
Centre Hospitalier François Quesnay
Mantes-la-Jolie, France
Centre Hospitalier Annecy Genevois
Metz-Tessy, 74374, France
Institut Curie
Paris, France
Institut Curie Saint Cloud
Saint-Cloud, France
Institut de Cancérologie Lucien Neuwirth
Saint-Etienne, France
Hôpital Foch
Suresnes, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Chantal Decroisette
CH Annecy Genevois
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 9, 2020
First Posted
November 23, 2020
Study Start
October 1, 2019
Primary Completion
June 5, 2020
Study Completion
June 5, 2020
Last Updated
November 23, 2020
Record last verified: 2020-11